NCT05290961

The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening

Status unknown Last updated 31 August 2023

What this trial tests

trial in Ovarian Neoplasms in 30 participants. Status unknown.

Timeline

9 March 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Chongqing University Cancer Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	9 March 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Conditions studied

• Ovarian Neoplasms — all drugs for Ovarian Neoplasms →

Sponsor

Chongqing University Cancer Hospital

Who can join

Adults 18 to 70, female only, with Ovarian Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Most ovarian cancer will relapse after standard therapy. Patients with recurrent ovarian cancer are resistant to platinum. Due to the high heterogeneity between ovarian cancer, individual precise therapy is of great importance. The study will establish ovarian cancer organoids, whose original tissues from the patients with advanced or recurrent ovarian cancer, their tumors cannot be excised completely. The organoids will be identified at the histopathological level and gene level for evaluating the consistency with the original tumor tissue. The drug's sensitivity and specificity are detected through the organoids model. Compared with the clinical efficiency of the actual drug regimen, the efficacy of the organoid drug screening model can be assessed. The aim is to construct a precise drug screening platform for advanced and recurrent ovarian cancer patients and innovate drug research and development.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Organoids: The current status and biomedical applications.
   Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
2. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
   Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
3. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
   Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
4. Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.
   Ciucci A, Buttarelli M, Fagotti A, Scambia G, et al · · 2022 · cited 32× · PMID 35705879 · DOI 10.1007/s00018-022-04395-y
5. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
   Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
6. Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.
   Chan WS, Mo X, Ip PPC, Tse KY. · · 2023 · cited 11× · PMID 37776168 · DOI 10.1002/cam4.6521
7. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
   Hu H, Sun C, Chen J, Li Z. · · 2024 · cited 9× · PMID 38509422 · DOI 10.1007/s00432-024-05654-0
8. Organoid development and applications in gynecological cancers: the new stage of tumor treatment.
   Li Y, Qin M, Liu N, Zhang C. · · 2025 · cited 6× · PMID 39819668 · DOI 10.1186/s12951-024-03086-z